RFA treatment, first introduced for the treatment of Barrett’s esophagus, was subsequently used to treat vascular mucosal lesions, such as gastric antral vascular ectasia (GAVE) or watermelon stomach and CRP. This evidence concerns the gene CRP and esophageal adenocarcinoma.